胃癌化疗在日本的现状精选.pptVIP

采用RECIST评价的患者中，S-1单药组有效率为26.9%,IRI-S组为41.5%,两者具有统计学显著差异（p＝0.035）. 两组的毒性均可耐受。 尽管IRI-S组比S-1单药组中位生存期（MST）延长了2.3个月，但总生存期（OS）并未显示出具有统计学显著差异的优势. 鉴于两组中有68例（22％）患者因生存时间的延长出乎意料而接受了审查，其后的随访需要更为精准以确认总生存期。 JCOG 8801治疗计划 总生存期-全部随机- 无复发生存期-全部随机- 总生存期- Ⅱ期- 总生存期- ⅢA期- 总生存期- ⅢB 期- S-1+CDDP was superior to S-1 in SPRITS in Japan. Now FLAGS trial is on-going in red country including Europe, United States, Australia and south America. This study is designed to evaluate the superiority of S-1+CDDP to 5-FU+CDDP. If S-1+CDDP is superior to 5-FU+CDDP, S-1+CDDP will become the standard treatment for advanced